The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...
Eli Lilly’s Mounjaro targets India’s $150 billion weight-loss market amid rising diabetes crisis
Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that having an overweight or obese trajectory during childhood is associated with an ...
Researchers analyzed prospective data on the dietary intake of 200,000-plus adults and noted how many died from cancer.
While currently available through the NHS only for specific cases, demand for this new generation of weight ... Danish pharmaceutical company Novo Nordisk, the creator of Ozempic and Wegovy ...
Hosted on MSN20d
Ozempic 'Significantly' Lowered 'Alcohol Craving' in First Clinical Trial, with Those Taking the Drug Drinking 40% LessA new study showed that semaglutide may help with ... in the Journal of the American Medical Association Psychiatry. In May 2024, Novo Nordisk, the manufacturer of Ozempic, announced it would ...
Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback